Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vofopitant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vofopitant SCHEMBL5153521 | 1.00 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL29711142 | 1.00 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL8316732 | 1.00 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL310338 | 0.99 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL7062769 | 0.99 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL8431760 | 0.99 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL30522777 | 0.99 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL8901341 | 0.99 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL2996010 | 0.99 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL30522778 | 0.99 | TACR1 (1.00) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024139979-A1 | USE OF VOFOPITANT FOR TREATING SCLERODERMA | 上海数因信科智能科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118252833-A | Use of Vofopitant for the treatment of pulmonary fibrosis | 上海数因信科智能科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-118252832-A | Use of Vofopitant for the treatment of scleroderma | 上海数因信科智能科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | ACER THERAPEUTICS INC. | 2021-02-04 | — | — | US | disclosed |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-08-22 | — | — | US | disclosed |
| US-20170231979-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-08-17 | — | — | US | disclosed |
| US-20170020855-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-01-26 | — | — | US | disclosed |
| US-20150272927-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2015-10-01 | — | — | US | disclosed |
| US-8093268-B2 | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| WO-2008090116-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | GLAXO GROUP LIMITED (GB) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008090117-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3, 5-DIAMIN0-6- (2, 3-DICHL0PHENYL) -L, 2, 4-TRIAZINE OR R (-) -2, 4-DIAMINO-5- (2, 3-DICHLOROPHENYL) -6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | GLAXO GROUP LIMITED (GB) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008090114-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-) | GLAXO GROUP LIMITED (GB) | 2008-07-31 | — | — | WO | disclosed |
| EP-0802912-B1 | PIPERIDINE DERIVATIVES HAVING TACHYKININ ANTAGONIST ACTIVITY | GLAXO GROUP LTD (GB) | 2004-10-13 | — | — | EP | disclosed |
| US-6020346-A | Piperidine derivatives having tachykinin antagonist activity | GLAXO WELLCOME INC. (US) | 2000-02-01 | — | — | US | disclosed |
| US-5843966-A | Piperidine derivatives | GLAXO GROUP LIMITED (GB) | 1998-12-01 | — | — | US | disclosed |
| EP-0720609-B1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LTD (GB) | 1998-11-11 | — | — | EP | disclosed |
| US-5703240-A | ANALGESICS; ANTIINFLAMMATORY AGENTS; NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS; GASTROINTESTINAL DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-30 | — | — | US | disclosed |
| EP-0802912-A1 | PIPERIDINE DERIVATIVES HAVING TACHYKININ ANTAGONIST ACTIVITY | GLAXO GROUP LIMITED (GB) | 1997-10-29 | — | — | EP | disclosed |
| WO-1996021661-A1 | PIPERIDINE DERIVATIVES HAVING TACHYKININ ANTAGONIST ACTIVITY | GLAXO GROUP LIMITED (GB) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | TACR1 226/4885 |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | TACR1 226/4885 |
| US-20150272927-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | VASP, PDE3A, PDE2A | TACR1 226/4885 |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | VASP, PDE3A, PDE2A | TACR1 226/4885 |
| US-20170231979-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | TACR1 226/4885 |
| US-20170020855-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | TACR1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.